Comunicación corta
Rituximab intralesional como tratamiento de linfoma folicular primario de conjuntiva recidivante
Intralesional rituximab in primary conjunctival follicular lymphoma relapsed
Leído
117
Vecesse ha leído el artículo
26
Total PDF
91
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 5 | 1 | 0 | 1 |
| 2023 8 | 1 | 2 | 3 |
| 2023 3 | 4 | 3 | 7 |
| 2022 2 | 1 | 0 | 1 |
| 2021 5 | 1 | 2 | 3 |
| 2020 5 | 1 | 0 | 1 |
| 2020 4 | 2 | 0 | 2 |
| 2020 2 | 1 | 2 | 3 |
| 2019 4 | 1 | 2 | 3 |
| 2019 1 | 1 | 2 | 3 |
| 2018 5 | 1 | 0 | 1 |
| 2018 3 | 1 | 0 | 1 |
| 2018 2 | 19 | 5 | 24 |
| 2018 1 | 27 | 1 | 28 |
| 2017 11 | 5 | 1 | 6 |
| 2017 10 | 1 | 0 | 1 |
| 2017 8 | 3 | 1 | 4 |
| 2017 7 | 18 | 0 | 18 |
| 2017 6 | 2 | 0 | 2 |
| 2017 2 | 0 | 4 | 4 |
| 2016 1 | 0 | 1 | 1 |
Mostrar todo
